Overview

Omegaven in Patients With Rheumatoid Arthritis (ORA-Trial)

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis constitutes that the fish-oil preparation (Omegaven) is superior to the preparation based on Soja-oil (Lipovenös)to reduce signs and symptoms in patients with active rheumatoid arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Humanis Klinikum Niederosterreich